

Title (en)  
DIRECT COMPRESSION FORMULATION AND PROCESS

Title (de)  
DIREKTVERPRESSUNGSFORMULIERUNG UND -VERFAHREN

Title (fr)  
FORMULATION DE COMPRESSION DIRECTE ET PROCÉDÉ

Publication  
**EP 3738585 B1 20221214 (EN)**

Application  
**EP 20177506 A 20050117**

Priority  
• US 53770604 P 20040120  
• US 60427404 P 20040825  
• EP 18165545 A 20050117  
• EP 15199440 A 20050117  
• EP 09157626 A 20050117  
• EP 05700976 A 20050117  
• EP 2005000400 W 20050117

Abstract (en)  
[origin: WO2005067976A2] Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into solid form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.

IPC 8 full level  
**A61K 9/20** (2006.01); **A61K 47/00** (2006.01); **A61P 3/00** (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01); **A61P 19/02** (2006.01); **A61P 19/10** (2006.01); **A61P 37/08** (2006.01); **A61P 43/00** (2006.01); **C07D 207/16** (2006.01)

CPC (source: EP KR NO RU US)  
**A61J 3/10** (2013.01 - RU); **A61K 9/2013** (2013.01 - EP NO US); **A61K 9/2018** (2013.01 - NO); **A61K 9/2054** (2013.01 - EP NO US); **A61K 9/2059** (2013.01 - EP NO US); **A61K 9/2072** (2013.01 - RU); **A61K 9/2077** (2013.01 - US); **A61K 9/2095** (2013.01 - EP NO US); **A61K 31/40** (2013.01 - KR NO RU US); **A61K 47/26** (2013.01 - RU); **A61K 47/36** (2013.01 - KR); **A61K 47/38** (2013.01 - RU); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 207/16** (2013.01 - EP US); **Y10T 428/268** (2015.01 - EP US)

Citation (examination)  
• NOVARTIS AG: "Proprietor's letter filed on 15-07-2020 in opposition proceedings EP15199440", 15 July 2020 (2020-07-15), pages 1 - 7, XP055810817, Retrieved from the Internet <URL:https://worldwide.espacenet.com/patent/search/family/034798877/publication/EP3023095A1?q=15199440.7>  
• JOHN EDGAR: "Declaration of Dr. Edgar John", 15 July 2020 (2020-07-15), pages 1 - 3, XP055810821, Retrieved from the Internet <URL:https://worldwide.espacenet.com/patent/search/family/034798877/publication/EP3023095A1?q=15199440.7>  
• STEFAN EPISKAMP: "Interlocutory decision concerning EP15199440", 7 May 2021 (2021-05-07), pages 1 - 10, XP055810834, Retrieved from the Internet <URL:https://worldwide.espacenet.com/patent/search/family/034798877/publication/EP3023095A1?q=15199440.7>

Citation (opposition)  
Opponent : Herzog IP Patentanwalts GmbH  
• WO 2006021455 A1 20060302 - NOVARTIS AG [CH], et al  
• WO 0004241 A1 20000127 - LOGAN JOHN [US]  
• WO 2005067976 A2 20050728 - NOVARTIS AG [CH], et al  
• LEON LACHMAN, HERBERT A. LIEBERMAN: "Theory and Practice of Industrial Pharmacy", 1 January 1970, LEA & FEBIGER, Great Britain, article GUNSEL WILLIAM C, CHARLES J. SWARTZ, AND JOSEPH L. KANIG: "Tablets", pages: 305 - 318, XP093131188  
• LIEBERMAN H A, LACHMAN L, SCHWARTZ J B: "Pharmaceutical Dosage Forms Tablets Volume 1", 1 January 1989, MARCEL DEKKER, US, ISBN: 978-0-8247-8044-9, article RALPH F SHANGRAW: "Compressed Tablets by Direct Compression", pages: 195 - 200, XP093131206  
• ARTHUR H KIBBE: "Handbook of Pharmaceutical Excipients Third edition", 1 January 2000, AMERICAN PHARMACEUTICAL ASSOCIATION, Washington, D.C, ISBN: 0-917330-96-X, article WHEATLEY T A: "Cellulose, Microcrystalline", pages: 102 - 105, XP093131213  
• ARTHUR H KIBBE: "Handbook of Pharmaceutical Excipients Third edition", 1 January 2000, AMERICAN PHARMACEUTICAL ASSOCIATION, Washington, D.C, ISBN: 0-917330-96-X, article KIBBE ARTHUR H: "Lactose", pages: 276 - 285, XP093131225  
• ARTHUR H KIBBE: "Handbook of Pharmaceutical Excipients Third edition", 1 January 2000, AMERICAN PHARMACEUTICAL ASSOCIATION, Washington, D.C, ISBN: 0-917330-96-X, article ALLEN L V, PE LUNER: "Magnesium Stearate", pages: 305 - 308  
• ARTHUR H KIBBE: "Handbook of Pharmaceutical Excipients Third edition", 1 January 2000, AMERICAN PHARMACEUTICAL ASSOCIATION, Washington, D.C, ISBN: 0-917330-96-X, article V CONWAY, M MULSKI.: "Sodium Starch Glycolate", pages: 501 - 504, XP093131233  
• PATEL, N.K. ; UPADHYAY, A.H. ; BERGUM, J.S. ; REIER, G.E.: "An evaluation of microcrystalline cellulose and lactose excipients using an instrumented single station tablet press", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 110, no. 3, 26 September 1994 (1994-09-26), NL, pages 203 - 210, XP023736129, ISSN: 0378-5173, DOI: 10.1016/0378-5173(94)90242-9  
Opponent : NOVARTIS AG  
• SHIKIFUMI KITAZAWA, IKUO JOHNO, YOKO ITO, SHIGEO TERAMURA, JUTARO OKADA: "Effects of hardness on the disintegration time and the dissolution rate of uncoated caffeine tablets", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 27, no. 10, 1 October 1975 (1975-10-01), pages 765 - 770, XP093161696, DOI: 10.1111/j.2042-7158.1975.tb09397.x  
• NAJIB, N. ; JALAL, I.: "Correlation between dissolution and disintegration rate constants for acetaminophen tablets", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 44, no. 1-3, 1 June 1988 (1988-06-01), NL, pages 43 - 47, XP025554371, ISSN: 0378-5173, DOI: 10.1016/0378-5173(88)90098-1

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR LV MK YU

DOCDB simple family (publication)

**WO 2005067976 A2 20050728; WO 2005067976 A3 20061116;** AR 049000 A1 20060621; AU 2005205055 A1 20050728; AU 2005205055 B2 20090611; BR 122018014389 B1 20230425; BR 122018073405 B1 20230425; BR PI0507007 A 20070605; CA 2552569 A1 20050728; CA 2552569 C 20121211; CY 1110522 T1 20150429; CY 1120575 T1 20190710; CY 1124770 T1 20221125; DE 602005015421 D1 20090827; DK 1715893 T3 20091109; DK 3023095 T3 20180820; DK 3366283 T3 20211122; EC SP066707 A 20061031; EC SP11006707 A 20110930; EC SP18089087 A 20181231; EP 1715893 A2 20061102; EP 1715893 B1 20090715; EP 1715893 B8 20091216; EP 2165703 A2 20100324; EP 2165703 A3 20120328; EP 3023095 A1 20160525; EP 3023095 B1 20180516; EP 3023095 B2 20231108; EP 3366283 A1 20180829; EP 3366283 B1 20210901; EP 3738585 A1 20201118; EP 3738585 B1 20221214; ES 2332920 T3 20100215; ES 2684325 T3 20181002; ES 2684325 T5 20240610; ES 2899417 T3 20220311; ES 2940341 T3 20230505; HK 1221663 A1 20170609; HK 1255731 A1 20190823; HR P20181270 T1 20181019; HR P20211766 T1 20220218; HU E039902 T2 20190228; HU E056586 T2 20220228; IL 176831 A0 20061031; JP 2007518760 A 20070712; JP 2012176968 A 20120913; JP 5122144 B2 20130116; JP 5739835 B2 20150624; KR 101259645 B1 20130430; KR 20060129270 A 20061215; LT 3023095 T 20180910; LT 3366283 T 20211210; MA 28305 A1 20061101; MX PA06008265 A 20060831; MY 138450 A 20090630; NO 20063739 L 20061020; NO 20200892 A1 20061020; NO 345116 B1 20201005; NZ 548351 A 20090828; NZ 578743 A 20110429; PE 20050686 A1 20051108; PH 12019501331 A1 20210607; PL 1715893 T3 20100331; PL 3023095 T3 20181031; PL 3366283 T3 20220117; PL 3738585 T3 20230417; PT 1715893 E 20091020; PT 3023095 T 20181019; PT 3366283 T 20211202; PT 3738585 T 20230130; RS 57561 B1 20181031; RS 62595 B1 20211231; RU 2006130009 A 20080227; RU 2766487 C2 20220315; SI 1715893 T1 20091231; SI 3023095 T1 20180928; SI 3366283 T1 20211231; TW 200534878 A 20051101; TW I374760 B 20121021; US 2008038341 A1 20080214; US 2011236479 A1 20110929; US 2012294939 A1 20121122; US 2014205663 A1 20140724

DOCDB simple family (application)

**EP 2005000400 W 20050117;** AR P050100182 A 20050119; AU 2005205055 A 20050117; BR 122018014389 A 20050117; BR 122018073405 A 20050117; BR PI0507007 A 20050117; CA 2552569 A 20050117; CY 091101062 T 20091014; CY 181100840 T 20180810; CY 211101034 T 20211129; DE 602005015421 T 20050117; DK 05700976 T 20050117; DK 15199440 T 20050117; DK 18165545 T 20050117; EC DI201889087 A 20181129; EC SP066707 A 20060718; EC SP11006707 A 20110804; EP 05700976 A 20050117; EP 09157626 A 20050117; EP 15199440 A 20050117; EP 18165545 A 20050117; EP 20177506 A 20050117; ES 05700976 T 20050117; ES 15199440 T 20050117; ES 18165545 T 20050117; ES 20177506 T 20050117; HK 16109923 A 20160818; HK 18114884 A 20181121; HR P20181270 T 20180803; HR P20211766 T 20050117; HU E15199440 A 20050117; HU E18165545 A 20050117; IL 17683106 A 20060713; JP 2006549999 A 20050117; JP 2012107450 A 20120509; KR 20067014506 A 20050117; LT 15199440 T 20050117; LT 18165545 T 20050117; MA 29205 A 20060724; MX PA06008265 A 20050117; MY PI20050199 A 20050119; NO 20063739 A 20060821; NO 20200892 A 20200810; NZ 54835105 A 20050117; NZ 57874305 A 20050117; PE 2005000075 A 20050119; PH 12019501331 A 20190613; PL 05700976 T 20050117; PL 15199440 T 20050117; PL 18165545 T 20050117; PL 20177506 T 20050117; PT 05700976 T 20050117; PT 15199440 T 20050117; PT 18165545 T 20050117; PT 20177506 T 20050117; RS P20180946 A 20050117; RS P20211399 A 20050117; RU 2006130009 A 20050117; SI 200530794 T 20050117; SI 200532218 T 20050117; SI 200532299 T 20050117; TW 94101577 A 20050119; US 201113154063 A 20110606; US 201213562415 A 20120731; US 201414226871 A 20140327; US 58605905 A 20050117